US pharmaceutical giant Johnson & Johnson reports new phase 3 data for the psoriasis drug Icotyde, icotrokinra.
After 112 weeks, 70 percent had clear or almost clear skin.
Complete clearance was achieved by 60 percent of patients with scalp psoriasis, 89 percent with genital psoriasis and 63 percent with symptoms on their hands or feet.
The safety profile remained stable, with no new safety signals.
